Consistent data was seen in a patient affected by mesothelioma who developed fatal neuroendocrine toxicity (insulin-dependent diabetes, hypophysitis, and a myasthenia-like syndrome) while he was on treatment with a dual mAb blocking PD1 and TIM3 [64]. This evidence concerns the gene HAVCR2 and type 1 diabetes mellitus.